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Abstract
Polycystic ovarian syndrome is the commonest cause of anovulatory infertility. This 
chapter will explore fertility treatment options for this condition including the risks, ben-
efits and success rates for different treatment methods. The importance of close patient 
monitoring with hormone levels and pelvic ultrasounds to ensure mono-ovulation and 
to avoid ovarian hyperstimulation syndrome will be highlighted.
Keywords: polycystic ovary syndrome, anovulation, obesity, ovulation induction, 
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1. Introduction
Polycystic ovarian syndrome (PCOS) is the commonest cause of anovulatory infertility 
[1]. Depending on the population studied between 5 and 18% of women of reproductive 
age suffer from PCOS, however not all of them are anovulatory or experience subfertility 
[2–4].
The aim of fertility treatment in women with subfertility and PCOS is to safely induce mono-
follicular ovulation resulting in the birth of a singleton child. Women undergoing fertility 
treatment with PCOS are at significant risk of both multi-follicular development and ovarian 
hyper-stimulation syndrome (OHSS), so they must be carefully counselled and monitored dur-
ing fertility treatment. It is imperative that prior to embarking on fertility treatment a patient’s 
health and weight is optimised. This chapter will explore the latest evidence for fertility treat-
ments for women with PCOS.
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Definition and diagnosis of PCOS
The current diagnosis for PCOS surrounds the cluster of signs and symptoms that the syn-
drome encompasses, namely anovulation, hyperandrogenaemia, insulin resistance and 
polycystic ovaries. The Rotterdam Criteria for diagnosis of PCOS requires two of the three 
diagnostic criteria, namely oligo- or anovulation, clinical or biochemical signs of hyperan-
drogenism and polycystic ovarian morphology (Table 1) [1].
There is discussion that the Rotterdam criteria is too broad and may be resulting in over 
diagnosis of the syndrome [5], especially in young women, prone to clinical signs of hyperan-
drogenism and who are more likely to have morphological features of polycystic ovaries on 
USS. Furthermore, when investigating a patient for possible PCOS, age, ethnicity and weight 
should be factored in.
Hyperandrogenic features, either biochemical or chemical, are seen in 60–80% of patients 
with PCOS [6]. Clinical features of hyperandrogenism correlate poorly with blood andro-
gen levels, especially in some ethnic groups, particularly South East Asian, with increased 
sebaceous gland susceptibility to circulating androgens. Serum androgen concentrations 
must be measured in the setting of more severe clinical findings to ensure other causes of 
hirsutism are excluded such as adrenal tumours or non-classical congenital adrenal hyper-
plasia (CAH).
Polycystic ovarian morphology definition is predominantly based on findings from 
a paper by Sonnard in 2003 comparing 214 ovaries of PCOS patients with 112 normal 
women’s ovaries to conclude that a diagnosis of polycystic ovaries should be more than 
12 follicles measuring between 2 and 9 mm per ovary or an ovarian volume of more than 
10cm3. This diagnostic criterion is now largely seen to be too broad with further studies 
and improvement in ultrasound techniques suggesting that either the diagnostic follicle 
number should be increased [7] or raised AMH levels should be included in the diagnostic 
criteria.
Oligo-ovulation or anovulation is suggested by either irregular cycles or a sup-optimal mid-
luteal phase progesterone. Cycles that are either shorter than 21 days or longer than 35 days 
are highly suggestive of anovulation, although It is recognised that even in adolescents with 
very short or protracted cycles ovulation can still occur, with obvious implications should 
pregnancy avoidance be required [8].
Two out of the following three criteria
1. Oligo- and/or anovulation
2. Clinical and/or biochemical signs of hyperandrogenism
3. Polycystic ovaries on ultrasound after exclusion of other aetiologies (congenital adrenal hyperplasia, androgen 
secreting tumours, Cushing’s syndrome)
Table 1. Revised ESHRE/ASRM Rotterdam consensus diagnostic criteria for PCOS.
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3. Lifestyle modifications and weight loss
The first line of treatment and advice to women with PCOS seeking fertility treatment 
should be to optimise health. This is true for all women considering pregnancy but impera-
tive for women with PCOS due to the commonly seen associations of obesity and metabolic 
disorders. Furthermore, as with any woman about to start to try to conceive, her doctor 
must stabilise any co-existing morbidities, and any medication prescribed must be safe for 
pregnancy.
While 9–18% of the female reproductive age population meet the criteria for PCOS, up to 
70% of obese women do [9]. Obese patients with PCOS have an associated increase in sever-
ity of the disease, not just from a fertility perspective but for all metabolic and psychological 
sequelae of the disorder, when compared with non-obese PCOS patients. Obesity is associ-
ated with an increased risk of anovulation, increased androgen production and decreased 
response to follicular stimulating hormone (FSH) equating to decreased fecundity both in 
natural conception and assisted reproductive techniques [10]. Risks to the foetus if concep-
tion does occur include increased rates of congenital anomalies (neural tube defects, ompha-
locele and cardiac defects) [11], increased rates of hypoglycaemia of the newborn and other 
complications of gestational diabetes and long-term greater risks of metabolic disease for life. 
Risks to the pregnant obese patient include greater incidence of hypertensive disorders in 
pregnancy, increased incidence of thromboembolic events, increased incidence of gestational 
diabetes, increased risks of operative delivery and increased risks of perineal trauma [11]. 
For all these reasons, it is imperative that patients embarking on fertility treatment are first 
counselled and advised to optimise their weight and aim for a body mass index (BMI) in the 
healthy range.
With a 5–10% weight reduction in patients with PCOS significant benefits are seen in all 
aspects of health, including reproductive health. Spontaneous ovulation is more likely and 
patient’s response to fertility treatment is more likely to be successful [12, 13]. Caloric restric-
tion, increased physical activity and weight loss medication can all play a role in helping 
patients achieve the necessary weight loss to either conceive spontaneously or have greater 
success with fertility treatments. There is limited data on live birth rates, however a loss of 
weight from an unhealthy weight range in PCOS patients is associated with an improved 
waist to hip ratio measurement, improved clinical and biochemical signs of hyperandrogen-
ism and improved insulin resistance [14].
A recent randomised control trial of 149 patients with PCOS and body mass index (BMI) 
between 27 and 41 kg/m2 compared 16 weeks of lifestyle modification (caloric restriction, 
weight loss medication and increased levels of physical activity), the combined oral con-
traceptive pill (COCP) or both interventions followed by 4 cycles of clomiphene citrate and 
timed intercourse. The researchers found significant weight loss in the lifestyle modifica-
tion group (mean weight loss −6.2%) and the combined group (mean weight loss −6.4%) 
when compared to the COCP only group. Superior cumulative ovulation rates were seen 
in the lifestyle group (60%) and the combined group (67%) compared with the COCP 
group (46%) after 4 cycles of clomiphene citrate. Live birth rates were not significantly 
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increased, although the study was not adequately powered for livebirth as an outcome, 
but were higher in the lifestyle (26%) and combined (24%) group compared with the COCP 
group (12%) [12].
Bariatric surgery can be considered in women with a BMI over 35 and who have had a failed 
attempt at weight loss with lifestyle modifications. Bariatric surgery improves markers of 
PCOS influencing fertility, namely anovulatory cycles, hormonal ratios and insulin resis-
tance, but comes with the increased risk of a malabsorptive state and disordered eating as 
well as psychological issues [15–17]. There are limited trials powered to confirm an absolute 
improvement in live birth rates following bariatric surgery. Pregnancy and fertility treat-
ments should be avoided for a minimum of 12 months after such surgery to reduce the preg-
nancy complications associated with bariatric surgery, such as; preterm birth and being small 
for gestational age. This is due to the profound catabolic state existing after surgery and 
the depletion of micro-nutrients from the diet [18]. Due to this enforced time delay, in the 
setting of an older woman with falling ovarian reserve, time for substantial weight loss or 
bariatric surgery may not be feasible to ensure a successful pregnancy. In these cases, with 
proper counselling, more leniency may be given to cut off levels of BMI to commence fertility 
treatment.
4. Metformin
Metformin is a biguanide antihyperglycaemic medication used in Type 2 diabetes mellitus. It 
acts by decreasing glucose levels through reducing hepatic glucose production and reducing 
intestinal absorption of glucose, overall reducing the level of insulin secretion. As PCOS has 
a strong association with hyperinsulinaemia and insulin resistance many patients with PCOS 
have been treated with metformin, and there is a substantial amount of research showing the 
beneficial effects of metformin on reproductive outcomes. There is strong evidence to show 
that within 1–3 months of commencing metformin treatment there is improvement in cycle 
regularity and improved ovulation rates [19]. Up to 50% of anovulatory women with PCOS 
will ovulate after treatment with metformin [20]. It is thought metformin acts by not only 
reducing insulin levels systemically, but also by directly acting on the ovary to alter gonado-
trophin levels [21]. Metformin use is associated with weight loss, greater than with lifestyle 
changes alone, and thus is associated with the reproductive benefits outlined in the weight 
loss effects above [22].
Metformin’s influence on reproductive outcomes has demonstrated an improvement in clini-
cal pregnancy rates, without an improvement in overall live birth rates, and does not appear 
to provide additional benefit when combined with clomiphene citrate, unless used in the 
profoundly overweight patient. A meta-analysis of 38 trials of nearly 3500 women showed 
that there was no increase in the live birth rate for women treated with metformin, either 
as a single agent (OR1.80 CI 0.52–6.16) or as an addition to clomiphene citrate. (OR 1.16, CI 
0.85–1.56) [23].
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However there is some evidence that metformin may improve live birth rates for women 
undergoing ovulation induction when combined with gonadotrophins. Two RCTS com-
paring the use of placebo versus metformin in ovulation induction with gonadotrophins 
for women with PCOS have shown a higher live birth rate (OR 2.31) in the metformin and 
gonadotrophin group compared with the placebo and gonadotrophin group, however the 
numbers studied were small [24, 25]. There was no observed increase in multiple pregnancy 
rates in these studies or others looking at clinical pregnancy rates only, with the addition of 
metformin [26].
From the studies outlined above metformin cannot be recommended as a treatment for ovula-
tion induction alone, however in obese or overweight women it can play a role in weight loss 
which may facilitate spontaneous ovulation in conjunction with clomiphene. There is some 
limited data that it may improve reproductive outcomes as an adjunct to ovulation induction 
treatment with gonadotrophins in women with diagnosed PCOS.
5. Clomiphene and anti-oestrogens
Clomiphene citrate is a selective oestrogen receptor modulator (SERM) used to induce ovula-
tion in anovulatory patients for over 50 years [27]. It will induce ovulation in around 75% of 
patients with PCOS. Increasing doses of clomiphene results in increased rates of ovulation, 
but not necessarily increased rates of pregnancy. Being a SERM, clomiphene acts on oestro-
gen receptors in the hypothalamus and pituitary, to increase follicular stimulating hormone 
(FSH) production, and on receptors in the endometrium and cervix with differing antagonist 
and agonist qualities depending on dose [28]. Clomiphene, particularly in higher doses, can 
produce a less receptive endometrial environment and a more hostile cervical mucus, which 
may negatively affect pregnancy rates.
Ovulation rates were studied at different doses for women with PCOS, with the finding that at 
a starting dose of 50 mg per day 46% of patients ovulate, 70% ovulate with 100 mg, 76% with 
150 mg and up to 90% at doses greater than 150 mg daily for 5 days [29]. As doses increase 
a lower percentage of the women who have not ovulated previously on the lower dose have 
success with the higher dose as the proportion of women with true clomiphene resistance 
increases. Patients are usually deemed clomiphene resistant, thought to affect around 15% of 
women with PCOS, if no follicle development is seen with 3 cycles of maximal dose (150 mg 
for 5 days) of clomiphene citrate [30]. Patients are more likely to be clomiphene resistant if 
they are obese and suffer from significant hyperandrogenism [31].
Evidence suggests women with PCOS undergoing fertility treatment with clomiphene have 
a cumulative pregnancy rate of around 45% after 4 cycles and 65% after 6 cycles [32], with a 
live birth rate of around 42% [33]. After 6 cycles of treatment the pregnancy rate falls despite 
regular ovulation, suggesting other subfertility issues may be present in the couple or the 
effects of high dose clomiphene is impacting the uterus.
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It is essential that clomiphene treatment, as with any ovulation induction treatment, must 
be monitored with serial transvaginal ultrasound examinations (TVUS) to monitor follicular 
development, and allow for cycle cancellation if a response with more than one dominant fol-
licle developing is seen. Monitoring treatment in this way keeps the rate of multiple pregnan-
cies to a minimum. The multiple pregnancy rate with clomiphene treatment is between 6.9–9% 
for twin pregnancies and less than 1% for higher order multiple pregnancy. Congenital mal-
formations have not been shown to be any higher in women taking clomiphene than women 
who spontaneously ovulated [34].
Clomiphene treatment is for the most part well tolerated with common side effects relating to 
the effects of hypoestrogenism including hot flushes, abdominal distention, nausea and breast 
tenderness being seen in 10–20% of patients. Side effects do not appear to be dose dependent, 
but rather a result of patient response.
The risk of ovarian hyperstimulation syndrome (OHSS) is theoretical with clomiphene 
use and if occurs is nearly always mild. Treatment dose should always be started low and 
increased only if ovulation has not occurred to avoid this risk.
Clomiphene has been the first line fertility treatment for women with PCOS for many years, 
however data is emerging that other treatment modalities have greater success and a move 
away from using clomiphene citrate in the first instance is being practiced.
6. Letrozole
Letrozole is an aromatase inhibitor inducing a hypo-oestrogen state by inhibiting the enzyme 
converting androgens to oestrone and oestradiol. A low serum oestradiol concentration 
results in increased pituitary FSH production, and consequently subsequent follicular devel-
opment and ovulation. It is licenced for the treatment of oestrogen sensitive breast cancers in 
postmenopausal women, but is gaining popularity in its currently off label use in producing 
mono-ovulation in women undergoing fertility treatment with PCOS.
Like clomiphene, letrozole is given in the early follicular phase of the cycle for 5 consecu-
tive days. Dosing is started low, usually at 2.5 mg to ensure response can be monitored 
and avoid cycle cancellation if an exaggerated follicular response is seen. Higher doses are 
associated with poorer endometrial thickness, but not at the levels seen with clomiphene 
citrate [35].
Compared with clomiphene citrate letrozole has been shown in a randomised controlled 
trial and a meta-analysis of six trials to be superior at inducing ovulation (the RCT showing 
relative risk (RR)1.28) and live-birth rates (RR 1.44) [36, 37]. These results were particularly 
evident for patients with a body mass index over 30 kg/m2, with no significant difference 
between the two treatment modalities in patients with a BMI of less than 30 kg/m2. The same 
study reported lower multiple pregnancy rates with letrozole compared with clomiphene use 
(3.4% vs. 7.4%), however the study was not powered for this outcome.
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Studies looking at foetal safety with letrozole use have found no significant difference in the 
rates of congenital anomalies in pregnancies conceived using letrozole, compared with clomi-
phene or spontaneous ovulation [38]. Side effects related to low oestrogen levels with letro-
zole appear to be less common than those seen with clomiphene use.
Particularly for patients who are obese (BMI over 30 kg/m2) letrozole can be considered as a 
first line treatment for mono-ovulation induction. For women with a BMI less than 30 kg/m2 
letrozole may lead to similar pregnancy rates to clomiphene, however the side effect profile 
and the possible lower multiple pregnancy rates may favour the use of letrozole.
7. Gonadotrophins
Gonadotrophins in the form of injectable recombinant FSH are used in women with PCOS 
to induce mono-ovulation, historically as a second-line treatment after a patient had failed 
clomiphene citrate treatment. The perceived risk of ovarian hyper-stimulation and multiple 
gestation has meant it has been overlooked as a first-line treatment. This view is changing 
with more evidence to support its use, particularly with low dose, step-up protocols with very 
close monitoring (Langdon et al. 2017 personal communication).
Patients with PCOS are particularly sensitive to FSH due to the high antral follicle count 
associated with the condition. It is imperative that the dose threshold to induce ovulation is 
reached gradually to reduce the risk of multiple follicles being recruited resulting in cycle 
cancellation, multiple pregnancy or even OHSS, as well as patient disappointment. In therapy 
naïve patients dosing usually begins at 25 or 37.5 IU/day increasing by small increments (usu-
ally 12.5 IUI) at a minimum of 7–10 days, if no response is seen on vaginal ultrasound moni-
toring or serum oestradiol levels [39]. Requirements for higher doses of FSH are often seen 
in women with a greater BMI, older age, insulin resistance and amenorrhoea compared with 
oligomenorrhoea [33].
The success of gonadotrophin ovulation induction is superior to clomiphene. An RCT of ther-
apy naïve women with PCOS compared to treatment with either clomiphene or low dose FSH 
for up to 3 cycles and found that treatment with FSH had a higher first cycle pregnancy rate 
(30% vs. 14.6%, 95% CI 5.3–25.8), overall pregnancy rate (58% vs. 44%, 95% CI 1.5–25.8) and 
live birth rate (47.4% vs. 36.9%.) [42].
Despite the increased success rates associated with gonadotrophin use the therapy has not 
been embraced as a routine first line fertility treatment for PCOS in many fertility centres due 
to older studies warning of increased complication rates with its use, and a lack of reimburse-
ment in some jurisdictions. Multiple gestation rates when FSH is used with the purpose of 
achieving of mono-ovulation are documented to be as low as 6%, comparable to clomiphene 
use [40]. This is achieved by strictly adhering to a low dose, slow step-up protocol as outlined 
above. It is further achieved by being wary of patients who may have a greater response to 
FSH treatment, namely younger patients, those with high AMH levels and those with nor-
mal BMI, and ensuring treatment is commenced on the lowest FSH dose possible, and only 
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increased after a period of up to 14 days with no response. Cancelling cycles when response is 
excessive is imperative to keeping multiple pregnancy rates down. Having a 5–20% cancella-
tion rate has been shown to be associated with a less than 2% higher order multiple pregnancy 
rate and no difference in pregnancy rates over 4 cycles, and patients should be thoroughly 
counselled about this [41].
OHSS is a risk with FSH use but with carefully monitored use as described above in 
women with PCOS the risk is minimal and almost completely avoidable. The risk is only 
present if too many follicles are stimulated, thus starting with a low dose of FSH, and 
making small incremental increases only when no response is seen over an extended 
period and having a low threshold for cancellation of the cycle, OHSS risk can be com-
pletely avoided.
A review of 591 cycles of ovulation induction with gonadotrophins in 268 PCOS patients 
in our unit demonstrated that adherence to a low dose step up protocol had success rates 
of 22% for their first cycle, 18% for second cycles and 7% for third cycles. Success rates fell 
steeply after a third cycle. Success rates were highest for women with normal BMI (<25 kg/
m2) and aged less than 35 years. Our multiple pregnancy rate was 2% with a cancellation 
rate of 13%. Over 591 cycles there were no cases of OHSS (Langdon et al. 2017, personal 
communication).
With careful administration and monitoring of a low-dose step up protocol, FSH ovulation 
induction is more successful and not associated with any greater risk than clomiphene. Many 
units are moving towards using this method as a first line treatment for PCOS patients. It is 
worth noting that success rates seem to fall after 3 cycles and consideration should be given to 
attempting other forms of fertility treatment if pregnancy has not been achieved by this point.
8. Laparoscopic ovarian drilling
Laparoscopic ovarian drilling is a longstanding treatment for anovulation for women with 
PCOS. It is of value if performed at the time of diagnostic laparoscopy as part of a general 
infertility investigation after fallopian tube patency has been demonstrated and a normal 
semen assessment has been documented. It also offers rural patients the ability to undergo 
ovulation induction treatment without the requirement for frequent blood tests and ultra-
sound examinations. Laparoscopic ovarian drilling improves ovulation rates likely through 
destruction of theca cells in the ovary that produce androgens resulting in increased FSH 
levels and reduced LH levels conducive to normal follicular development. As a first line treat-
ment, randomised trials have shown similar results for ovulation, conception and live birth 
rates when compared with up to 6 cycles of clomiphene [42] and has a likely ongoing success 
rate without the risk of multiple pregnancy from clomiphene.
Compared with gonadotrophins, similar rates of pregnancy and live birth rate were seen in a 
meta-analysis of randomised trials comparing the two methods but with far lower multiple 
pregnancies and no risk of OHSS [43]. Potential drawbacks of laparoscopic ovarian drilling 
Testes and Ovaries - Functional and Clinical Differences and Similarities68
include the possibility of pelvic adhesion development and possible reduction in ovarian 
reserve. Studies looking at repeat laparoscopies following ovarian drilling procedures have 
shown adhesions in over 30% of patients treated with diathermy and 50% of patients treated 
with laser [44]. Reduced serum AMH concentrations, antral follicle counts, and ovarian vol-
ume as well as raised FSH levels following ovarian drilling support the notion that ovarian 
drilling has a possible negative impact on ovarian reserve.
9. In vitro fertilisation (IVF) and reducing OHSS rates
In vitro fertilisation (IVF) is usually reserved for women with PCOS who have failed other 
treatments or with additional issues compromising their fertility. Women with PCOS, as 
has been discussed previously, are especially at risk of developing OHSS when undergo-
ing IVF, but as a consequence of this often respond very well to IVF stimulation produc-
ing many follicles and oocytes. It is a careful balance to ensure a patient responds well 
to FSH dosing, but not so well that they are at significant risk of OHSS. A patient with 
PCOS undergoing an IVF stimulation cycle needs to have a well monitored, individualised 
stimulation regime to reduce the risk of OHSS and minimise the chance of cycle cancella-
tion. Her age, antral follicle count, anti-Mullerian hormone level (AMH) and BMI should 
all be considered when starting a cycle and planning the starting dose of FSH. Monitoring 
with transvaginal ultrasound and serum oestradiol concentrations should be very thor-
ough with a low threshold for cancelling a cycle or employing other methods to reduce the 
risk of OHSS.
Other ways of avoiding OHSS in these high-risk patients is to routinely use GnRH antago-
nists rather than agonists to prevent the LH surge [45]. Two meta-analyses have shown lower 
rates of OHSS when GnRH antagonists are used compared to use of an agonist, but possibly 
at the cost of slightly reduced pregnancy rates as GnRH agonists generally result in enhanced 
follicle recruitment [46, 47].
Coasting can be a way to prevent cancellation of the cycle if oestrogen levels are rising too 
rapidly and there is concern the patient may be at risk of OHSS. Coasting involves with-
holding FSH therapy while continuing LH suppression with a GnRH agonist or antagonist. 
This is done until oestradiol levels fall to an acceptable level, if they do not a low threshold 
must be maintained to cancel the cycle. A review employing 3 days of coasting in the event 
of high oestradiol levels had minimal effect on pregnancy rates and importantly a low OHSS 
rate (<2%) [48]. If coasting occurred for longer than 3 days pregnancy rates were affected and 
thus the suggestion is made that after 3 days of coasting if oestradiol levels have not fallen, 
consideration of cycle cancellation is warranted.
There is growing evidence of the benefits of metformin use prior to IVF cycles in women with 
PCOS to reduce the risk of OHSS. Two meta-analyses have found similar results with a signifi-
cant reduction in OHSS rates in patients pre-treated with metformin (OR 0.27, 95%CI 0.16–0.46 
and OR 0.29, 95%CI 0.18–0.49) [49, 50], although metformin treatment was not shown to affect 
the live birth rate compared with placebo treatment in either study.
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In vitro oocyte maturation (IVM) is a new technique that eliminates the risk of OHSS [51] 
and is well suited to patients with PCOS due to their high antral follicle count. Immature 
oocytes are collected and matured in culture before undergoing either IVF or ICSI fertilisa-
tion techniques. It requires minimal amounts of stimulation prior to antral follicle collection 
eradicating the risk of OHSS and also reducing medication costs to the patient. Data suggests 
that the live birth rate may be reduced in comparison with standard IVF cycles, especially in 
fresh cycles, however for frozen embryo transfer cycles pregnancy, miscarriage and live birth 
rates are not significantly different [52].
It is imperative that clinicians who put women with PCOS through IVF stimulation cycles 
are vigilant for the development of OHSS in these patients and monitor and treat accordingly 
(Table 2).
10. Conclusion
PCOS is the most common cause of anovulatory infertility and thus is responsible for a large 
percentage of women seeking fertility treatment. When implementing a treatment plan for 
a patient with PCOS their metabolic health and weight are important factors that must be 
Selection of patients
  IVF only in appropriately selected patients following unsuccessful ovulation induction or other specific fertility 
issues requiring treatment with IVF
  Consideration of in vitro oocyte maturation in very high risk patients
  Pre-treatment with Metformin and continue through IVF cycle
Cycle management
  Well monitored, individualised stimulation regime
  Low threshold for cycle cancellation
  GnRH antagonist protocol
  Consider cycle coasting for up to 3 days if concern high for OHSS
At time of trigger injection
  Use an agonist trigger and adopt a “freeze-all embryos” approach to the cycle
  Consideration of the use of a dopamine agonist to reduce OHSS risk
Luteal phase management
  Continue ovarian down-regulation into the luteal phase if no embryo transfer is planned
  Early consideration of adopting a “freeze-all” approach
  If proceeding to a fresh embryo transfer: the replacement of a single embryo
Table 2. Methods for reduction of rates of OHSS in women with PCOS undergoing IVF.
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addressed and managed prior to embarking on assisted reproductive techniques. The risks 
of OHSS and multi-follicular development in patients with PCOS means that care must be 
taken with close, careful monitoring to ensure mono-ovulation is achieved and the risks of 
multiple pregnancy and OHSS is kept to a minimum. If this approach is adopted the infertil-
ity treatment for these women is both safe and effective and patients should be reassured of 
these facts.
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